Loading ...
Sorry, an error occurred while loading the content.

NATAP: New HCV Antisense Drug Study Starts

Expand Messages
  • claudine intexas
    NATAP http://natap.org/ _______________________________________________ New HCV Antisense Drug Avi BioPharma initiates hepatitis C clinical trial Avi BioPharma
    Message 1 of 2 , Oct 4, 2005
    • 0 Attachment
      NATAP http://natap.org/
      _______________________________________________
      New HCV Antisense Drug

      Avi BioPharma initiates hepatitis C clinical trial

      Avi BioPharma has begun an exploratory safety and efficacy clinical trial using its proprietary Neugene antisense compound AVI-4065 in the treatment of hepatitis C virus.

      29 Sep 2005, 16:50 GMT - The multi-center study will assess the safety, tolerability, pharmacokinetics and viral response to daily subcutaneous administration of AVI-4065 among healthy volunteers and patients with chronic active hepatitis C virus (HCV).

      "There is a large, unmet medical need for effective HCV treatments, as the current treatment regimen is successful in less than half of the patients infected with genotype 1 HCV, the most common form of the virus in the US," said Dr Denis Burger, CEO of Avi. "The ability of our Neugene antisense to specifically target the HCV virus may offer a safer and more efficacious drug for patients," added Dr Burger.

      HCV is a single-stranded RNA virus. Because HCV and other single-stranded RNA viruses have relatively simple genetic structures, they are attractive targets for AVI's Neugene antisense, which is designed to target conserved portions of the viral genetic code that are not likely to mutate over time.

      Source: Datamonitor Newswire
      _______________________________________________
      NATAP nataphcv mailing list -- nataphcv@...

      This is an annoucement-only mailing list. Do not reply.

      To unsubscribe: send a blank email to nataphcv-request@... with a subject of unsubscribe.


      For more information, see http://seven.pairlist.net/mailman/listinfo/nataphcv

      _______________________________________________


      ----------

      _______________________________________________
      NATAP nataphcv mailing list -- nataphcv@...

      This is an annoucement-only mailing list. Do not reply.

      To unsubscribe: send a blank email to nataphcv-request@... with a subject of unsubscribe.


      For more information, see http://seven.pairlist.net/mailman/listinfo/nataphcv

      _______________________________________________


      [Non-text portions of this message have been removed]
    • avansi7465
      That s encouraging! Thanks, Anne ... From: claudine intexas Sent: Oct 4, 2005 7:02 PM To: Web Warriors
      Message 2 of 2 , Oct 5, 2005
      • 0 Attachment
        That's encouraging! Thanks, Anne

        -----Original Message-----
        From: claudine intexas <claudineintexas@...>
        Sent: Oct 4, 2005 7:02 PM
        To: Web Warriors <HepCWebWarriors@yahoogroups.com>, gi <giworld-hepatitis@yahoogroups.com>
        Subject: [GIWorld-Hepatitis] NATAP: New HCV Antisense Drug Study Starts



        NATAP http://natap.org/
        _______________________________________________
        New HCV Antisense Drug

        Avi BioPharma initiates hepatitis C clinical trial

        Avi BioPharma has begun an exploratory safety and efficacy clinical trial using its proprietary Neugene antisense compound AVI-4065 in the treatment of hepatitis C virus.

        29 Sep 2005, 16:50 GMT - The multi-center study will assess the safety, tolerability, pharmacokinetics and viral response to daily subcutaneous administration of AVI-4065 among healthy volunteers and patients with chronic active hepatitis C virus (HCV).

        "There is a large, unmet medical need for effective HCV treatments, as the current treatment regimen is successful in less than half of the patients infected with genotype 1 HCV, the most common form of the virus in the US," said Dr Denis Burger, CEO of Avi. "The ability of our Neugene antisense to specifically target the HCV virus may offer a safer and more efficacious drug for patients," added Dr Burger.

        HCV is a single-stranded RNA virus. Because HCV and other single-stranded RNA viruses have relatively simple genetic structures, they are attractive targets for AVI's Neugene antisense, which is designed to target conserved portions of the viral genetic code that are not likely to mutate over time.

        Source: Datamonitor Newswire
        _______________________________________________
        NATAP nataphcv mailing list -- nataphcv@...

        This is an annoucement-only mailing list. Do not reply.

        To unsubscribe: send a blank email to nataphcv-request@... with a subject of unsubscribe.


        For more information, see http://seven.pairlist.net/mailman/listinfo/nataphcv

        _______________________________________________


        ----------

        _______________________________________________
        NATAP nataphcv mailing list -- nataphcv@...

        This is an annoucement-only mailing list. Do not reply.

        To unsubscribe: send a blank email to nataphcv-request@... with a subject of unsubscribe.


        For more information, see http://seven.pairlist.net/mailman/listinfo/nataphcv

        _______________________________________________


        [Non-text portions of this message have been removed]




        Welcome to GIHepWorld

        Post message: GIWorld-Hepatitis@yahoogroups.com
        Subscribe: GIWorld-Hepatitis-subscribe@yahoogroups.com
        Unsubscribe: GIWorld-Hepatitis-unsubscribe@yahoogroups.com
        List owner: GIWorld-Hepatitis-owner@yahoogroups.com
        URL to this page: http://groups.yahoo.com/group/GIWorld-Hepatitis

        Yahoo! Groups Links
      Your message has been successfully submitted and would be delivered to recipients shortly.